2021 Summit Agenda

Download The 2021 Agenda

Networking Available All Day


  • 8:00am – 6:00pm EST: Tuesday, November 3rd 

As the main agenda progresses throughout the day, you will have the choice of listening in to / participating in the live content or spend more of your time networking with your peers.

Here is how you will be able to achieve this, outside of the networking sessions on the agenda

  • See who’s in the room – you will be able to message all live attendees and connect with those who respond.
  • Schedule 1-2-1 video calls with your connections at any time that suits you.
  • Open Networking – think of this as the event lobby where you can replicate those all-important “water-cooler” moments.

You will be able to hop seamlessly between networking and on-going agenda sessions at any point.

With networking available all day, this will provide you with even more opportunities to meet your potential future partners and collaborators.


Main Agenda

  • Wednesday, September 22nd
Wednesday, September 22nd
8:00am EST

Conference Platform Opens

The conference platform opens before the agenda starts, giving you time to plug the presentations, panels and discussions into your agenda for the rest of the day. This also gives you plenty of time to get familiar with the platform.

9:00am EST

Chair’s Opening Remarks and Keynote Presentation: Harnessing NK Cells against cancer through IL-15 Pathway Activation

  • Design and preclinical characterization of NKTR-255, a novel IL-15 pathway agonist
  • Therapeutic efficacy in preclinical models of liquid and solid tumors
  • Phase I dose-escalation study data: pharmacodynamics and safety

Willem Overwijk, VP, Oncology Research, Nektar Therapeutics

9:35am EST

Wellness Break

9:35am EST

Presentation: Notable Advancements for Next-Gen Cytokine Therapeutics – The Story so Far 

Dr. Jon Wigginton, Chief Medical Officer, Cullinan Oncology

10:05am EST

Wellness Break

Deep-Dive into the Main Challenges of Cytokine Therapeutic Development

10:10am EST

Panel Discussion: What Key Challenges do we Need to Overcome to Unlock the Full Potential of Cytokine Therapeutics?

Over the past 20 years there has been considerable advancements in using Cytokines as Therapeutics. Shared knowledge across the field has enabled progression to be made with a deeper insight. However gaps in scientific understanding of the intricacies of cytokine pathways may pose as a limit to further advancements being made.

  • Will the particular engineering strategy affect how it is delivered, dosage and therapeutic half-life?
  • How can we enhance localization and does the answer lie with antibodies or interaction with the microenvironment?
  • What is the best-practice approach for utilizing IL-2, IL-12 & IL-15?
  • What are the gaps in our current scientific understanding that we need to address in order to move forward?

Dr. Carl Walkey, Senior Vice President Corporate Development, Neoleukin Therapeutics

Dr. Carlos Mayo, MD Executive Director R&DAlkermes

10:50am EST

Wellness Break

10:55am EST

Presentation: How to Increase the Therapeutic Index and Is the Answer Activity on Demand?

Dr. Dario Neri, Chief Executive Officer, Philogen

11:20am EST

Wellness Break

11:25am EST

Presentation: Cullinan Oncology’s AMBER Platform: Cytokine Fusion of IL-2 & IL-12

Dr. Naveen Mehta, Director of Preclinical Research & Development, Cullinan Oncology

11:45am EST

Wellness Break

11:50am EST

Panel Discussion: What can We Learn from Preclinical Research that Will Uncover the Most Favourable Therapeutic Cytokines? 

What can we learn from pre-clinical research in order to sustain the efficacy of these Next-Gen Cytokine Therapeutics all the way through to meet patient needs?

  • How can we combat the short half-life of cytokine therapies for increased success?
  • Which approaches best work to control the activity of cytokines in the body?
  • Which strategies have been most successful in dealing with toxicities for patients?
  • What can the drug discovery and development stage do to ensure success in clinical trials?

Prof. Michael Dougan, Assistant Professor, Harvard Medical School, Massachusetts General Hospital

12:30pm EST

Lunch

The Next-Gen Cytokine Therapeutics Summit includes an extended break in the middle to give you ample time for lunch and another chance to catch up on the day job. Or if you have time, you can use this break for 1-2-1 meetings or open networking.

Deep-Dive Case Study Presentations

1:20pm EST

Presentation: How AskGene are Harnessing the Full Potential of Cytokine Therapeutics- Prodrug Technology

  • We hear how OncoSec have negated toxicity using Proprietary Electroporation 
  • OncoSec share insights into their current clinical trials for melanoma and triple negative breast cancer.

Dr. Yuefeng Lu, Chief Scientific Officer, AskGene Pharma

1:45pm EST

Wellness Break

1:50pm EST

Presentation: Alkermes Clinical presentation of IL2/Nemvaleukin.

Dr. Carlos Mayo, MD Executive Director R&D, Alkermes

2:15pm EST

Wellness Break

2:20pm EST

Presentation: Immunocytokines as a Means to Optimize Immunotherapy in Prostate Cancer 

Dr. Ravi Madan, Clinical Director Genitourinary Malignancy, National Cancer Institute 

2:45pm EST

Wellness Break

2:50pm EST

Presentation: MDNA55- IL-4 & IL-13 Superkines as a Trojan Horse and IL-2 the Superagonist for Cancer Immunotherapy

Dr. Fahar Merchant, Chief Executive Officer, Medicenna

3:15pm EST

Wellness Break

3:20pm EST

Presentation: Xilio’s Masking Technologies Applied to IL-2, IL-12 & IL-15.

Dr. Ronan O’Hagan, Senior Vice President, Research & Translational Science, Xilio Therapeutics

3:45pm EST

Wellness Break

3:50pm EST

Presentation by Sotio 

Representative from Sotio

4:15pm EST

Wellness Break

4:40pm EST

Panel Discussion: Where does the Future Lie for Cytokine Therapies? 

Looking forward, what will define success? Our deeper biological understanding? The elimination of current challenges?

  • What defines the success of cytokines as therapeutics?
  • Will we uncover a ‘gold standard’ in the industry?
  • To what length/extent will there be crossover between disease treatments?
  • How can we predict which patients will respond best, to which cytokine therapies?

Dr. Carl Walkey, Senior Vice President Corporate Development, Neoleukin Therapeutics

Dr. Richard Sachse, Chief Medical Officer, Sotio

5:05pm EST

Close of The 2nd Annual Next-Gen Cytokine Therapeutics Summit

Download The 2021 Agenda